Crohn's disease

Perianal fistulizing Crohn's disease causes major quality-of-life problems and is often hard to treat. This trial tests risankizumab in people who did not respond to or could not tolerate other standard therapies, and it...

The trial is testing a personalized approach that uses CLE to find foods that directly disrupt the intestinal barrier and then removes those foods to see if patients feel and biologically improve. If successful, it could...

Wearable-derived digital biomarkers could enable earlier, less burdensome detection of IBD flares and better remote monitoring if they reliably predict mucosal inflammation.

This OLE study follows patients who lost response to ustekinumab every-8-week dosing and evaluates whether increasing to every-4-week dosing maintains efficacy and safety long-term. That question is directly relevant to...

Researchers are investigating whether a specific gut bacterium (Pilosibacter rotomagensis) is linked to lower intestinal inflammation after surgery for ileal Crohn's disease. If true, this could point toward new...

A fungal infection (paracoccidioidomycosis) can closely mimic Crohn’s disease on clinical, endoscopic, and histologic grounds, which risks misdiagnosis and harmful treatment delays—especially in patients from endemic...

The study suggests a decade-long preclinical phase of IBD detectable by blood metabolites, which could open opportunities for earlier identification of people at risk for Crohn’s disease and for studying early disease...

This trial suggests a structured whole-food diet may reduce subclinical intestinal inflammation (measured by fecal calprotectin) in asymptomatic children and young adults with Crohn's disease—offering a non-formula,...

Long-term Phase 3 extension data suggest guselkumab (Tremfya) may provide sustained clinical and endoscopic remission for some adults with moderate-to-severe Crohn's disease, which could expand treatment options for...

Holiday-related stress, disrupted routines, and dietary changes can increase the chance of IBD symptom flares. Simple, practical steps can reduce stress and help maintain symptom control during the season.

A positive pre‑IND response from the FDA makes it more likely this stem‑cell therapy will reach a formal Phase 2 trial, which could eventually expand treatment options for people with refractory or fistulising Crohn’s...

If true, the finding explains why symptoms can return after remission: the gut lining may remain biologically vulnerable even when inflammation seems controlled. That could point to new approaches aimed at 'molecular...

Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.

Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications.

Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from seekingalpha.com.

Long-term control of symptoms and intestinal inflammation is a major need in Crohn's disease. Three-year data showing sustained clinical and endoscopic remission and high rates of steroid-free remission could be...

Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.

Long-term (3-year) data on a biologic for Crohn's disease may indicate how durable treatment benefits and steroid-free remission can be for people considering or already on biologic therapy.

Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.

Perianal fistulas are a common and debilitating complication of Crohn’s disease that often need medical and surgical care. A Phase 3 trial reporting improved fistula remission with an IL-23–targeting therapy could offer...

Patients and clinicians may see continued availability and promotion of Skyrizi and Rinvoq across IBD indications, which can affect prescribing options and market competition. Sales growth and approvals also influence...

Based on the title and source metadata, this appears to be a patient story related to Crohn's disease and Community and awareness. The original article is from sports.yahoo.com.

Perianal Crohn’s disease causes major symptoms and affects long-term outcomes; understanding surgical options and the role of combined medical–surgical care can help patients and clinicians plan treatment. The review...

Long-term control of inflammation and healing of draining fistulas are important for people with Crohn’s disease; these FORTIFY OLE analyses suggest durable benefit with risankizumab in responders through several years...

Early human data suggest PALI-2108 reaches intestinal tissue and produced short-term clinical, endoscopic, and biomarker changes in very small Phase 1 cohorts, supporting larger Phase 2 trials that could determine if...

A breath-based VOC test could offer a noninvasive, point-of-care way to help detect or screen for colon diseases including IBD. This study shows preliminary promise—especially for ulcerative colitis—but is early-stage...

A sizable minority of people newly diagnosed with IBD—about 1 in 5 with Crohn’s and 1 in 10 with ulcerative colitis—received no IBD-specific drugs within the first year. Understanding who is untreated and why could...

Early Phase 1 findings suggest a gut-targeted PDE4 prodrug may engage its target in diseased tissue and produce early improvements in symptoms, endoscopy, and tissue inflammation — findings that, if confirmed in Phase 2,...

People with IBD often ask about dietary supplements. This systematic review suggests some randomized-trial evidence that polyphenol supplements—especially curcumin—may help induce clinical improvement in ulcerative...

Based on the title and source metadata, this appears to be a patient education related to Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease. The original article is from msn.com.

Conference analyses describe how subcutaneous infliximab performs after stopping IV treatment and when compared with IV infliximab for ileal/ileocolonic Crohn's — information that could affect treatment decisions for...

This study describes how often people newly diagnosed with IBD go on biologic or JAK inhibitor therapy and what happened to them over five years — including hospital visits and surgery — which helps set expectations for...

The study suggests that about one-quarter of IBD patients treated with advanced therapies develop difficult-to-treat disease, and identifies timing of therapy, age, and specific therapy choice as predictors.

Based on the title and source metadata, this appears to be a video related to Crohn's disease, Inflammatory bowel disease, and Stricture. The original article is from hmpgloballearningnetwork.com.

Based on the title and source metadata, this appears to be a video related to Crohn's disease, Inflammatory bowel disease, and Procedures and surgery. The original article is from hmpgloballearningnetwork.com.

New long‑term and real‑world data for risankizumab and upadacitinib were presented at ACG 2026, which may influence treatment considerations for people with difficult‑to‑treat Crohn's disease and ulcerative colitis.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Capsule Endoscopy. The original article is from gastroendonews.com.

Cure8 found this source from cureus.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Complications. Open the original article for the full details.

New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...

Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Infliximab.

The study points to a possible noninvasive brain-based biomarker that correlates with intestinal fibrosis severity in Crohn’s disease, a complication that’s hard to detect and treat. This could eventually help identify...

MRE is a noninvasive imaging test commonly used to evaluate small-bowel Crohn’s disease, especially when disease is beyond the reach of endoscopy or when repeated follow-up imaging is needed. It helps detect...

Patients and clinicians exploring new, less-invasive options for fibrostenotic colonic Crohn's disease may be interested because this study reports that intralesional PRP after balloon dilation is feasible and appears...

IBD cases are increasing in Sub-Saharan Africa but care and research remain limited and driven by high-income country priorities. Region-specific research and policy changes could improve diagnosis, treatment access, and...

The study identifies a bacterial mechanism (T6SS) that may help AIEC strains compete with normal gut microbes and colonize the intestinal mucosa — a process relevant to Crohn’s disease biology and future...

Cure8 could only read part of this source from einnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Tests and monitoring.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Infliximab, and Anti-TNF. The original article is from Frontiers in pediatrics.

The study suggests pulmonary nodules are more common in people with Crohn’s disease and that age and certain medications (not disease phenotype) may better predict nodule burden — information that could influence how...